Statistics from Altmetric.com
We thank Dr Zeidler for his interest in our manuscript,1 expressed in his recent letter to the editor.2 While Dr Zeidler raises interesting questions regarding methotrexate (MTX) bioavailability and the differences between oral and subcutaneous formulations of MTX, these are outside the scope of the CONCERTO study. Thus, it is important to reiterate that the objective of the study was to assess the oral dose of (MTX), which when co-administered with the tumour necrosis factor inhibitor, adalimumab (ADA), is required to optimise the benefit:risk profile in patients with early rheumatoid arthritis (RA), who were MTX naive. We agree with Dr Zeidler that this is not the usual course, nor one generally recommended by the European League Against Rheumatism (EULAR), of initiating a biological therapy for the treatment of RA; however, it was critical to assess …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.